Join
Live feed
·
PRReleasevia Quantisnow
Cytokinetics Incorporated logo
Royalty Pharma plc logo

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

ByQuantisnow·Wall Street's wire, on your screen.
CYTK· Cytokinetics IncorporatedRPRX· Royalty Pharma plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYTK (Cytokinetics Incorporated), RPRX (Royalty Pharma plc) and more on Quantisnow.